drugset
drugset / Trial / NCT06359821

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

NCT06359821 ↗

Phase 0 Completed 4 enrolled Sichuan University
NaSingle-groupOpen-labelOther

Summary

A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in metastatic castration resistant prostate cancer

Timeline

Start
2024-05-17
Primary completion
2024-10-14
Completion
2024-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ZA-001 Other / unclassified — Intravenous

Indications

metastatic prostate carcinoma